The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
At the conclusion of a Phase IIb study, adding Medivir's TMC435 to ribavirin and pegylated interferon more than doubled the success rate for Hepatitis C previous non-responders.
Continue reading »Based on previous encouraging results, Pharmasett's PSI-7977 will begin Phase 3 testing in three distinct Hepatitis C trials - all without interferon.
Continue reading »Based on early study results, Abbott's new CEO states they can offer future treatments capable of curing 90 percent of Hepatitis C virus cases - without interferon.
Continue reading »Based on its great treatment potential, Biotica has applied for a patent for Sangamides, a new class of drugs targeting the Hepatitis C virus.
Continue reading »After just three months of a Phase 2b study, Setrobuvir with pegylated interferon and ribavirin led to undetectable viral levels in over three quarters of previous Hepatitis C treatment non-responders.
Continue reading »Results from a newly published study reveal a way to predict who can be cured of Hepatitis C, providing motivation for affected individuals to complete treatment.
Continue reading »A partnership has been formed between Inovio Pharmaceuticals and VGX International to co-develop therapeutic vaccines for both Hepatitis C and Hepatitis B.
Continue reading »Phase 2A human trial confirms that, when coupled with interferon and ribavirin, experimental drug BIT225 has strong antiviral effect against the Hepatitis C virus.
Continue reading »In the air, nitric oxide is a toxic gas - but in the body it may aid Hepatitis C combination therapy.
Continue reading »About three months after Victrelis was approved in Europe as the third drug in a triple combination therapy for Hepatitis C, the European Union grants approval to Incivo -Victrelis's only competition.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
